Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Apr;77(4):429-38.
doi: 10.1136/jnnp.2005.072926. Epub 2005 Nov 23.

Clinical trials in mild cognitive impairment: lessons for the future

V Jelic  1 , M Kivipelto, B Winblad
Affiliations
Review

Clinical trials in mild cognitive impairment: lessons for the future

V Jelic et al. J Neurol Neurosurg Psychiatry. 2006 Apr.

Erratum in

  • J Neurol Neurosurg Psychiatry. 2006 Jul;77(7):892

Abstract

Mild cognitive impairment (MCI) is an operational definition for a cognitive decline in individuals with a greater risk of developing dementia. The amnestic subtype of MCI is of particular interest because these individuals most likely progress to Alzheimer's disease (AD). Currently hypothesised therapeutic approaches in MCI are mainly based on AD treatment strategies. Long term secondary prevention randomised clinical trials have been completed in amnestic MCI populations, encompassing agents with various mechanisms of action: acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine), antioxidants (vitamin E), anti-inflammatories (rofecoxib), and nootropics (piracetam). The design of clinical trials in MCI is influenced by study objectives and definition of primary end points: time to clinical diagnosis of dementia, and AD in particular, or symptom progression. As none of the drugs previously shown to have clinical efficacy in AD trials or benefit in everyday practice have met the primary objectives of the respective trials, design of future clinical trials in MCI should be further developed particularly as regards the selection of more homogeneous samples at entry, optimal treatment duration, and multidimensional and reliable outcomes.

PubMed Disclaimer

Conflict of interest statement

Competing interests: the authors have not received research grants from any of the pharmaceutical companies marketing anti‐dementia drugs, neither have they have stocks in any of these companies. Dr Bengt Winblad received consultancy fees for advisory board meetings from most companies marketing anti‐dementia drugs. Dr Miia Kivipelto received consulting fees for an advisory board meeting from Pfizer. All authors received fees for lecturing or organising education sponsored by Novartis.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Schneider L S. Current therapeutic trials. In: Iqbal K, Winblad B, eds. Alzheimer's disease and related disorders. Research advances. Bucharest: “Ana Aslan” International Academy of Aging, 2003639–651.
    1. Petersen R C. Mild cognitive impairment trials. Nat Rev Drug Discov 20032646–653. - PubMed
    1. Petersen R C, Grundman M, Thomas R.et al Donepezil and vitamin E as treatments for mild cognitive impairment. Neurobiol Aging 200425(Suppl 2)S20
    1. Gold M, Francke S, Nye J S.et al Impact of APOE genotype on the efficacy of galantamine for the treatment of mild cognitive impairment. Neurobiol Aging 200425(Suppl 2)S521
    1. Goldstein H R, Gold M. Galantamine in the treatment of patients with mild cognitive impairment: baseline demographics and psychometric testing results. Neurobiol Aging 200425(Suppl 2)S472–S473.

MeSH terms